MDxHealth SA (NASDAQ:MDXH) Short Interest Down 42.6% in December

MDxHealth SA (NASDAQ:MDXH) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 15,027 shares, a decline of 42.6% from the November 30th total of 26,198 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 122,196 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 122,196 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

MDxHealth Price Performance

NASDAQ MDXH traded up $0.14 on Tuesday, hitting $3.49. 124,527 shares of the company’s stock were exchanged, compared to its average volume of 124,796. The stock has a 50-day moving average of $3.83 and a 200-day moving average of $3.38. The stock has a market cap of $164.81 million, a price-to-earnings ratio of -5.44 and a beta of 1.59. MDxHealth has a 52 week low of $1.35 and a 52 week high of $5.33. The company has a current ratio of 1.14, a quick ratio of 1.02 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Analysts expect that MDxHealth will post -1.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. BTIG Research reissued a “buy” rating and set a $7.00 target price on shares of MDxHealth in a report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MDxHealth in a research report on Wednesday, October 8th. TD Cowen lifted their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Lake Street Capital increased their target price on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

Institutional Investors Weigh In On MDxHealth

Hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new position in MDxHealth during the 3rd quarter worth approximately $48,000. Lido Advisors LLC bought a new stake in shares of MDxHealth during the third quarter worth $48,000. Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the third quarter worth $53,000. Hudson Bay Capital Management LP bought a new position in shares of MDxHealth in the 3rd quarter valued at $70,000. Finally, Bank of America Corp DE lifted its stake in shares of MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after acquiring an additional 14,769 shares during the last quarter.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.